Literature DB >> 9690137

Watanabe rabbits with heritable hypercholesterolaemia: a model of atherosclerosis.

G Aliev1, G Burnstock.   

Abstract

Many factors play important roles in the development of atherosclerotic lesions. The leading risk factor for atherosclerosis is familial hypercholesterolaemia (FH). FH is a genetic disease characterized by a deficiency of receptors for low density lipoprotein (LDL) on the plasmalemma of endothelial cells, a high level of serum LDL, and early development of atherosclerosis and skin xanthoma. Watanabe and colleagues have developed a line of rabbits with unprovoked hypercholesterolaemia, increased blood level of LDL, pronounced atherosclerosis and skin xanthoma. These Watanabe Heritable Hyperlipidaemic (WHHL) rabbits possess an inheritable mutation of one gene, similar to that in human FH. The morphogenesis of atherosclerosis in patients with FH is characterized by multifocal deposit of lipids in the stromal cells of thymus, spleen, skin, interstitial and parenchymatous cells of kidneys and the presence of some single foam cells in aorta. The manifestation of atherosclerotic lesions in WHHL rabbits increases progressively with age but the presence of atherosclerotic lesions in newborn WHHL rabbits suggest that the process may commence in utero. Moreover, the main mass of plasma cholesterol in WHHL rabbits is first found in LDL and to a lesser degree in lipoproteins of intermediate density. This is contrary to diet-induced atherosclerosis in rabbits where the main mass of serum cholesterol is found in very low density beta-lipoproteins. Thus the distribution of cholesterol among lipoprotein fractions differs from that in WHHL rabbits. Atherosclerotic damage of arteries in WHHL rabbits goes through several stages. During the progression of intimal damage, lipid and foam cell deposits are found in the internal surface together with developing plaques and increased content of lipids in the tunica media. Calcification often follows this process. The main factors initiating atherosclerosis in WHHL rabbits are adhesion of leukocytes and platelets to endothelial cells and the accumulation of lipids in the aortic wall. The deposits of lipids in macrophages and intimal smooth muscle cells in WHHL rabbits occurs mostly at the expense of cytoplasmic neutral lipid particles with some accumulation in lysosomes. Hypertension as a risk factor increases the area of atherosclerotic damage in all arterial vessels in WHHL rabbits, particularly in the thoracic and abdominal aorta. Morphogenesis of the development of atherosclerosis in WHHL and diet-induced atherosclerosis in rabbits was similar, but differs from rats with heritable hypercholesterolaemia. Damage or loss of endothelial cells can predispose the atherosclerotic vessels to vasospasm and can leave vessels unprotected against vasoconstrictor stimuli. The development of the WHHL model has not only given insight into the mechanisms of development of familial hypercholesterolaemia but has also provided a model for assessing various therapeutic approaches for the prevention and treatment of atherosclerosis.

Entities:  

Mesh:

Year:  1998        PMID: 9690137     DOI: 10.14670/HH-13.797

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  20 in total

1.  Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries.

Authors:  P Zoldhelyi; Z Q Chen; H S Shelat; J M McNatt; J T Willerson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway.

Authors:  Nalini M Rajamannan; Malayannan Subramaniam; Frank Caira; Stuart R Stock; Thomas C Spelsberg
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

Review 3.  Animal models of atherosclerosis.

Authors:  Fatemeh Ramezani Kapourchali; Gangadaran Surendiran; Li Chen; Elisabeth Uitz; Babak Bahadori; Mohammed H Moghadasian
Journal:  World J Clin Cases       Date:  2014-05-16       Impact factor: 1.337

Review 4.  Hyperlipidaemia and cardioprotection: Animal models for translational studies.

Authors:  Ioanna Andreadou; Rainer Schulz; Lina Badimon; Adriana Adameová; Petra Kleinbongard; Sandrine Lecour; Panagiota-Efstathia Nikolaou; Ines Falcão-Pires; Gemma Vilahur; Nicholas Woudberg; Gerd Heusch; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2020-01-17       Impact factor: 8.739

5.  A novel adenylyl cyclase type 5 inhibitor that reduces myocardial infarct size even when administered after coronary artery reperfusion.

Authors:  Jie Zhang; Daniel Levy; Marko Oydanich; Claudio A Bravo; Seonghun Yoon; Dorothy E Vatner; Stephen F Vatner
Journal:  J Mol Cell Cardiol       Date:  2018-05-22       Impact factor: 5.000

Review 6.  Atherosclerosis: humoral and cellular factors of inflammation.

Authors:  A C Langheinrich; R M Bohle
Journal:  Virchows Arch       Date:  2005-02-02       Impact factor: 4.064

Review 7.  Reassessment of statins to retard the progression of aortic stenosis.

Authors:  Nalini M Rajamannan
Journal:  Curr Cardiol Rep       Date:  2007-04       Impact factor: 2.931

8.  Ultrastructural changes in atherosclerotic plaques following the instillation of airborne particulate matter into the lungs of rabbits.

Authors:  Erin M Tranfield; Stephan F van Eeden; Kazuhiro Yatera; James C Hogg; David C Walker
Journal:  Can J Cardiol       Date:  2010 Aug-Sep       Impact factor: 5.223

Review 9.  Animal models for the atherosclerosis research: a review.

Authors:  Li Xiangdong; Liu Yuanwu; Zhang Hua; Ren Liming; Li Qiuyan; Li Ning
Journal:  Protein Cell       Date:  2011-04-06       Impact factor: 14.870

Review 10.  Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease.

Authors:  Gjumrakch Aliev; Mark A Smith; Mark E Obrenovich; Jack C de la Torre; George Perry
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.